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(57) ABSTRACT 
Production of products by engineered bacteria is increased 
by regulating cellular respiration. Cellular respiration is 
controlled by reducing electron transfer enzyme activity. 
Some examples of electron transfer enzymes include NADH 
dehydrogenases, Succinate dehydrogenases, ubiquinone 
synthesis, cytochrome 0, and cytochrome D. In one 
example, deletion of UbiCA prevents respiration. Respira-
tion can the be controlled by addition of ubiquinone or 
expression of ubiCA. 
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REDUCED ACTIVITY OF UBICA IN E. COLI 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a 35 U.S.C. Section 371 of PCT/ 
US2007/077947 filed Sep. 7, 2007, which claims priority to 
U.S. Provisional Application 60/824,879 filed Sep. 7, 2006, 
both incorporated by reference in their entirety. 
FEDERALLY SPONSORED RESEARCH 
STATEMENT 
This invention was made with govermnent support under 
Grant No. BES-0222691 awarded by the National Science 
Foundation. The govermnent has certain rights in the inven-
tion. 
REFERENCE TO MICROFICHE APPENDIX 
Not applicable. 
FIELD OF THE INVENTION 
The invention relates to increased production of products 
by engineered bacteria by limiting respiration, thus conserv-
ing carbon for production even in the presence of excess 
oxygen. Specifically, the invention relates to a lmbiCA 
bacteria and its uses. 
BACKGROUND OF THE INVENTION 
The energetic state of microbial cells is very important 
during cell growth and product production. Currently, sig-
nificant numbers of valuable products are produced through 
anaerobic fermentation. However, productivity, mainly pro-
duction rate, of these processes is usually hampered by slow 
cell growth and low culture density. This is because under 
anaerobic conditions the cell generates much less energy 
from the nutrient; it mostly derives its energy through 
glycolysis that only yields two moles of ATP per mole of 
glucose consumed. This ATP yield is much lower than that 
2 
cially for large bioreactors. Variation in extent of aeration is 
a problem even in those situations where near complete 
oxygen saturation is desired. Any increased supply of oxy-
gen will favor cell growth and subsequently decrease the 
5 product yield. 
A second strategy is to perform the process in two stages. 
The first stage is to grow the cell under aerobic conditions 
and then switch to anaerobic conditions for product forma-
tion. This strategy avoids the possibility of oxygen oversup-
lO ply and guarantees a certain product yield for the second 
stage. However, the supply of ATP still is low during the 
product formation stage. There are also biological complexi-
ties that arise during the transition (proper synthesis and 
activation of required proteins and cofactors, triggering of 
15 cellular stress responses). 
What is required to improve production in engineered 
bacterial cells is a balance between energy generation 
through aerobic respiration and carbon atom conservation by 
limited respiration. By limiting respiration, the cell will not 
20 "waste" carbon atoms even when the oxygen supply is 
abundant. At the same time, a sufficient supply of ATP will 
be available for cell growth and product formation through-
out the fermentation processes. Strain respiration can be 
maintained at levels required for specific bioproduction 
25 needs, thus optimizing respiration and carbon conservation. 
SUMMARY OF THE INVENTION 
The Invention is generally directed to engineered bacterial 
30 cells having a balance between energy generation through 
aerobic respiration and carbon atom conservation by limited 
respiration. Disruption, mutation, inactivation, or complete 
deletion of electron transfer genes can be used to control 
respiration. The invention improves the performance of 
35 anaerobic processes, particularly those processes requiring 
significant energy for substrate uptake, product formation, or 
processes that do not perform well due to a lack of electron 
acceptors. 
In one embodiment, ATP is limited through control of 
40 aerobic respiration. This approach provides a limited carbon 
flow for energy generation independent of oxygen supply; 
thus this approach also conserves substrate carbon atoms for 
product formation (hence be able to maintain high product of aerobic respiration, however, the remaining carbon is 
conserved for product formation. Certainly, a higher energy 
yield through aerobic respiration can be achieved, but only 45 
at the expense of releasing carbon atoms stored in the 
feedstock (hence lower product yields). 
yield). Aerobic respiration can be limited in two ways: 
1. Introducing a disruption in a step involved in the 
normal electron transfer chain. 
2. Express the gene involved in electron transfer at a 
controlled or reduced level The aerobic respiratory chain of Escherichia coli (E. coli) 
For example, the invention can be achieved by reducing is composed of a number of membrane-bound, multisubunit 
enzymes located within the cytoplasmic membrane. Dehy-
drogenases such as NADH dehydrogenase or succinate 
dehydrogenase reduce ubiquinone to ubiquinol within the 
cytoplasmic membrane. Ubiquinol diffuses within the mem-
brane bilayer and is oxidized by either of two quinol oxidase 
complexes: the cytochrome O complex or the cytochrome D 
complex. For a complete review of E. coli respiration, see 
Ingledew and Poole (1984) incorporated herein by refer-
ence. 
50 activity of one or more NDH, SDH, UbiCA, CytO, or CytD. 
In one embodiment, ubiCA is deleted, and in another 
embodiment a mutant ubiCA with reduced activity is 
expressed. Deletion of the ubiCA operon prevents produc-
tion of ubiquinone. Electron transfer can then be regulated 
55 by adding ubiquinone or controlling exogenous ubiCA 
Two operating procedures have been developed in an 
attempt to strike an ideal balance between energy generation 60 
through aerobic respiration (for better cell growth and cell 
"fitness") and carbon conservation. One approach is to 
operate the bioreactor under microaerobic conditions. This 
reactor configuration provides a slight increase in ATP 
supply and limits the amount of carbon lost during aerobic 65 
respiration. However, it is technically difficult to maintain a 
constant microaerobic environment in real processes, espe-
expression. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1: Optical density 
FIG. 2: Lactate Yield 
DESCRIPTION OF EMBODIMENTS OF THE 
INVENTION 
Ubiquinone (Coenzyme Q) is an essential component of 
bacterial respiratory chains. The first committed step in the 
US 9,562,224 B2 
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inactivate (100%) gene product by completely preventing 
transcription and/or translation of active protein. 
The term "exogenous" indicates that the protein or nucleic 
acid is a non-native molecule introduced from outside the 
biosynthetic pathway is the formation of 4-hydroxybenzoate 
from chorismate by the enzyme chorismate pyruvate-lyase 
encoded by the ubiC gene. The 4-hydroxybenzoate is pre-
nylated by 4-hydroxybenzoate octaprenyltransferase 
encoded by the ubiA gene. The two genes are linked at 91.5 
min in the E. coli chromosome (see e.g, AP _004540 and 
AP _004541), and are found in all bacterial species with 
homologies ranging from to as low as 33% (while still being 
recognized as chorismate-pyruvate lyase, see e.g., 
NP _932913) and 24% (while still being recognized as 10 
polyprenyltransferase, see e.g., ZP _00987621). 
5 organism or system without regard to species of origin. For 
example, an exogenous peptide may be applied to the cell 
culture; an exogenous RNA may be expressed from a 
recombinant DNA transfected into a cell; or a native gene 
NADH-CoQ reductase in E. coli is encoded by either of 
two different membrane-bound NADH dehydrogenases 
(NDH-1 and NDH-2). Succinate dehydrogenase (SDH) 
reduces succinate to fumarate and reduces ubiquinone to 15 
ubiquinol. The Cyto complex is encoded by cyoABCDE 
operon and Cytd encoded by the cydAB operon. 
Carboxylic acids described herein can be a salt, acid, base, 
or derivative depending on structure, pH, and ions present. 
For example, the terms "succinate" and "succinic acid" are 20 
used interchangeably herein. Chemicals used herein, includ-
ing formate, glyoxylate, lactate, malate, oxaloacetate 
(OAA), phosphoenolpyruvate (PEP), and pyruvate, can be 
found in the NATIONAL LIBRARY OF MErncrNE® PUBCHEM™ 
database (pubchem.ncbi.nlm.nih.gov) incorporated herein 25 
by reference Bacterial metabolic pathways including the 
Krebs cycle (also called citric acid, tricarboxylic acid, or 
TCA cycle) can be found in Principles of Biochemistry 2nd 
ed., by Lehninger (1993), incorporated herein by reference, 
may be under the control of exogenous regulatory 
sequences. 
As used herein "recombinant" is relating to, derived from, 
or containing genetically engineered material. 
A gene or cDNA may be "optimized" for expression in E. 
coli or other bacterial species using the codon bias for the 
species. Various nucleotides can encode a single peptide 
sequence. Understanding the inherent degeneracy of the 
genetic code allows one of ordinary skill in the art to design 
multiple nucleotides which encode the same amino acid 
sequence. NCBI™ provides codon usage databases for 
optimizing DNA sequences for protein expression in various 
species. 
In calculating "% identity" the unaligned terminal por-
tions of the query sequence are not included in the calcu-
lation. The identity is calculated over the entire length of the 
reference sequence; thus short local alignments with a query 
sequence are not relevant ( e.g., % identity=number of 
aligned residues in the query sequence/length of reference 
sequence). Alignments are performed using BLAST homol-
ogy alignment as described by Tatusova TA & Madden TL 
as well as other biochemistry texts. 
The terms "operably associated" or "operably linked," as 
used herein, refer to functionally coupled nucleic acid 
sequences. 
30 (1999) FEMS Microbial. Lett. 174:247-50. The default 
parameters were used, except the filters were turned OFF. As 
of Jan. 1, 2001 the default parameters were as follows: 
"Reduced activity" is defined herein to be at least a 75% 
reduction in protein activity, as compared with an appropri-
ate control species. Preferably, at least 80, 85, 90, or 95% 
reduction in activity is attained, and in the most preferred 
embodiment, the activity is eliminated (100% or "inactiva-
tion"). Proteins can be inactivated with inhibitors, by muta-
tion, or by suppression of expression or translation, and the 
like. By "null mutant" or "null mutation" what is meant is 
that protein activity is completely inactivated. In one 
example, the control plasmid is inserted without the gene of 
interest. In another example, the gene of interest is com-
pletely removed by recombination. Additionally, the gene of 
interest may be removed by inactivation, mutation, or trun-
cation which eliminates activity. 
"Overexpression" or "overexpressed" is defined herein to 
BLASTN or BLASTP as appropriate; Matrix=none for 
BLASTN, BLOSUM62 for BLASTP; G Cost to open gap 
35 default=5 for nucleotides, 11 for proteins; E Cost to extend 
gap [Integer] default=2 for nucleotides, 1 for proteins; q 
Penalty for nucleotide mismatch [Integer] default=-3; r 
reward for nucleotide match [Integer] default= 1; e expect 
value [Real] default=lO; W word size [Integer] default=ll 
40 for nucleotides, 3 for proteins; y Dropoff (X) for blast 
extensions in bits ( default if zero) default=20 for blastn, 7 
for other programs; X dropoff value for gapped alignment 
(in bits) 30 for blastn, 15 for other programs; Z final X 
dropoff value for gapped alignment (in bits) 50 for blastn, 25 
45 for other programs. This program is available online at 
NCBI™ (www.ncbi.nlm.nih.gov/BLAST/). 
Common restriction enzymes and restriction sites are 
found at NEB® (New England Biolabs®, www.neb.com) 
and Invitrogen® (www.invitrogen.com). ATCC®, American 
50 Type Culture Collection™ (www.atcc.org) has an extensive 
collection of cell strains that are publicly available and 
be greater than wild type activity, preferably above 125% 
increase, more preferably above 150% increase in protein 
activity as compared with an appropriate control species. 
Preferably, the activity is increased 100-500%. Overexpres-
sion is achieved by mutating the protein to produce a more 
active form, a more stable form, or a form that is resistant to 
inhibition, by removing inhibitors, adding activators, and the 55 
like. Overexpression can also be achieved by removing 
repressors, adding multiple copies of a gene to the cell, 
up-regulating an existing gene, adding an exogenous gene, 
and the like. 
incorporated herein by reference. 
TABLE 1 
ABBREVIATIONS 
Abbr Term 
CytC cytochrome C 
The terms "disruption" and "disruption strains," as used 
herein, refer to cell strains in which the native gene is 
mutated, deleted, interrupted, or down-regulated in such a 
way as to decrease the activity of the gene. A gene is 
completely (100%) reduced by knockout or removal of a 
portion or the entire gene sequence. Use of a frame shift 
mutation, early stop codon, point mutations of critical resi-
dues, or deletions or insertions, and the like, can completely 
60 ;~; 
Ap!ApR 
ATCC® 
CoQ 
Cm 
Cn 
65 ColEl 
Em 
flavin mononucleotide 
fumarate reductase 
arnpicillin/arnpicillin resistance 
American Tissue-type Culture Collection 
coenzyme Q or ubiquinone 
chloramphenicol 
carbenicillin 
gram-negative origin of replication 
erythromycin 
US 9,562,224 B2 
Abbr 
FAD 
GC-MS 
JCT 
Km/KmR 
Mal 
MLSR 
Nal 
NCBJTM 
NDH 
OAA 
Orill 
Ox/00 
PEP 
PYR 
SDH 
Sm/SmR 
Sue 
Tc 
ThiRJcmR 
wt 
5 
TABLE I-continued 
ABBREVIATIONS 
Term 
flavin adenine dinucleotide 
gas chromatography-mass spectroscopy 
isocitrate 
kanarnycin/kanarnycin resistance 
malate 
macrolide, lincosarnide and streptograrnin A resistance 
nalidixic acid 
National Center for Biotechnology Information 
NADH dehydrogenase 
oxaloacetate 
gram-positive origin of replication 
oxacillin/oxacillin resistance 
phosphoenolpyruvate 
pyruvate 
succinate dehydrogenase 
streptomycin/streptomycin resistance 
succinate 
tetracycline 
thiamphenicol/chloramphenicol resistance 
wild-type 
Plasmids and strains used in certain embodiments of the 
invention are set forth in Table 2. 
TABLE 2 
PLASMIDS AND STRAINS 
Plasmid/Strain Genotype Ref 
pDHK29 Cloning vector CmR Phillips, 2000 
pTrc99A Cloning vector ApR PHARMACIA® 
pTrcHisTOPO Expression vector w/Trc promoter, INVITROGEN ® 
His Tag 
pUBICA pTrcHisTOPO_ w/ubiCA This work 
MG1655 Wild type (F-A-) Guyer, 1988 
AMSOOl L\.ubiCA This work 
UbiCA AMSOOl (pUBICA) This work 
6 
active aerobically). Thus, the metabolic pattern of the 
lrnbiCA mutant strain behaves similar to one that is grown 
anaerobically, even in the presence of air. 
Addition of different amounts of ubiquinone to the culture 
5 increased the final optical density and reduced the amount of 
lactate accumulated. The mutant strain responded to ubiqui-
none supplementation in a graded manner. The reduction in 
lactate formation suggests that the electron transfer chain is 
partially recovered and the cells are capable using oxygen as 
10 the electron acceptor. However, the mutant strain did not 
fully recover even when the concentration was increased to 
400 µM. It is possible that the low solubility ofUQ-1 in the 
medium limits the uptake of this molecule. Another expla-
nation might be that some intermediate products in the 
15 ubiquinone biosynthesis pathway are necessary for full 
recovery and restoration of the cell. These experiments 
demonstrate recovery by the exogenous addition of ubiqui-
none and control of cellular respiration rates using ubiqui-
none supplementation. 
20 
EXAMPLE 2 
Expression of UbiCA 
25 Complementation experiments were performed by trans-
30 
35 
forming AMSOOl with pUBICA. The growth characteristics 
and metabolic patterns were fully recovered by the intro-
duction of a plasmid carrying a normal ubiCA gene to the 
lrnbiCA mutant ( data not shown). Expression of exogenous 
UbiCA demonstrates influence of growth behavior and 
metabolic patterns in an aerobic E. coli culture by manipu-
lating the supply of the ubiquinone. By manipulating expres-
sion of the ubiCA operon, the amount of ubiquinone can be 
controlled and respiration can be tailored to the production 
process. 
REFERENCES 
When plasmids are used, the effect of host/plasmid inter-
40 
action is minimized by comparing three different systems 
All references are listed herein for the convenience of the 
reader. Each is incorporated by reference in its entirety. 
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EXAMPLE 1 
Limiting UQ-1 
45 
We sought to study the effect of exogenous supplemen- 50 
tation of ubiquinone-1 (UQ-1) to a lrnbiCA mutant strain, 
AMSOOl on cell respiration by measuring both cell growth 
and lactate yield, as an example of product formation. This 
mutant cannot produce ubiquinone due to a disruption 
(deletion) in ubiCA. 55 
Aerobic shake flask experiments with this mutant strain 
were carried out in 125-ml shake flasks containing 10 ml of 
LB medium supplemented with 20 g/L of glucose in a rotary 
shaker at 37° C. and 250 rpm. The final optical density and 
the specific lactate yield after 24 hours are summarized in 60 
FIGS. 1 and 2. 
2. Ingledew and Poole, "The Respiratory Chains of Escheri-
chia coli." Microbial. Rev. 48:222-71 (1984). 
3. Quarino, et al., "An ELISA method for the identification of 
salivary amylase." J Forensic Sc. (4): 973-6 (2005). 
4. Aluoch, et al., "Development of an oral biosensor for 
salivary amylase using a monodispersed silver for signal 
amplification." Anal Biochem. 240(1): 136-44 (2005). 
What is claimed is: 
1. An engineered bacterial cell comprising: 
a) a disruption in the ubiCA operon, and 
b) a vector comprising controlled expression of an exog-
enous ubiCA gene. 
2. The engineered bacterial cell of claim 1, further com-
prising reduced activity of an electron transfer enzyme 
selected from the group consisting ofNADH dehydrogenase 
(NDH), Succinate dehydrogenase (SDH), Cytochrome 0 
(Cyto ), Cytochrome D (Cytd), and combinations thereof. 
The lrnbiCA mutant strain grows very poorly and pro-
duces a large amount oflactate. The lrnbiCAmutant, due to 
the disruption in the electron chain, cannot use oxygen as the 
electron receptor even grown under aerobic conditions. 
Instead, the cell opted to recycle the NADH to NAD+ 
through the formation of lactate (the ethanol pathway is not 
3. The engineered bacterial cell of claim 2, wherein said 
cell has a deletion of one or more genes selected from the 
group consisting of ndh-1, ndh-2, sdh, cyoA, cyoB, cyoC, 
65 cyoD, cydA, cydB, and combinations thereof. 
4. A method of increasing product yield in an engineered 
bacterial cell comprising: 
US 9,562,224 B2 
7 8 
a) culturing the engineered bacterial cell of claim 1; 
b) regulating electron transfer activity by addition of 
ubiquinone or by manipulating expression of said 
exogenous ubiCA gene; and 
c) isolating a product from said cell. 5 
5. The method of claim 4, wherein said cell has a deletion 
of one or more genes selected from the group consisting of 
ndh-1, ndh-2, sdh, cyoA, cyoB, cyoC, cyoD, cydA, cydB, 
and combinations thereof. 
6. An engineered bacterial cell comprising: 10 
a) a disruption in a ubiA gene, a UbiC gene, or combi-
nations thereof, and 
b) a vector allowing controllable expression of an added 
exogenous ubiCA gene. 
7. A method of increasing product yield in an engineered 15 
bacterial cell comprising: 
a) culturing the engineered bacterial cell of claim 6; 
b) regulating electron transfer activity in said cell by 
addition of ubiquinone or by manipulating expression 
of said added exogenous ubiCA gene; and 20 
c) isolating a product from said cells. 
* * * * * 
